Evicenter
MarkdownMedical informationP&T meetings
VK2735

Chronic weight management

Last updated
184 sources

Product information and disease descriptionProduct descriptionProduct informationPharmacology

Pharmacokinetics

9 evidence topics · 8 sources

Subcutaneous formulation: pharmacokinetic parameters at 5.0 mg weekly in the phase 2 trial
DoseCmax (ng/mL)AUC0-168 (ng*h/mL)T1/2 (h)
VK2735 5.0 mg“1,120”“158,000”“171”
Oral formulation: bioavailability, half-life, and food effect

No evidence found.

Distribution, metabolism, and elimination pathways

No evidence found.